Myasthenia Gravis Trial, Recruiting (NCT06909253)

Myasthenia Gravis Trial, Recruiting NCT06909253 Sponsor: AstraZeneca Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT06909253 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with generalised Myasthenia Gravis (a muscle weakness condition), have never previously been treated with a type of drug called a complement inhibitor, and are currently receiving a medicine called ravulizumab through a special national drug programme in Poland.
People who are willing to take part and have signed a consent form agreeing to participate.
People who have been vaccinated against a specific type of bacterial infection called meningococcal disease (caused by N. meningitidis).

Who may not be able to join:

People who are planning to take part in another clinical trial for generalised Myasthenia Gravis at the same time as, or after, their first ravulizumab treatment through the national drug programme.
People who have difficulty understanding or communicating due to cognitive (thinking or memory) difficulties, unwillingness to cooperate, or language barriers that would prevent them from fully understanding the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06909253

Sponsor: AstraZeneca

Phase: Not Applicable

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 1-877-240-9479

More information: https://clinicaltrials.gov/study/NCT06909253

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with generalised Myasthenia Gravis (a muscle weakness condition), have never previously been treated with a type of drug called a complement inhibitor, and are currently receiving a medicine called ravulizumab through a special national drug programme in Poland.
People who are willing to take part and have signed a consent form agreeing to participate.
People who have been vaccinated against a specific type of bacterial infection called meningococcal disease (caused by N. meningitidis).

Who may not be able to join:

People who are planning to take part in another clinical trial for generalised Myasthenia Gravis at the same time as, or after, their first ravulizumab treatment through the national drug programme.
People who have difficulty understanding or communicating due to cognitive (thinking or memory) difficulties, unwillingness to cooperate, or language barriers that would prevent them from fully understanding the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AstraZeneca

Registry

ClinicalTrials.gov

Start date

15 May 2025

Est. completion

31 December 2029

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov